25-GI-142-MSD(MK-1084-012): A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS

Grants and Contracts Details

StatusActive
Effective start/end date10/27/25 → 10/27/27

Funding

  • Merck Sharp & Dohme Corporation: $2.00